Clopidogrel Bisulfate or Clopidogrel bisulphate is a thienopyridine-class antiplatelet pharmaceutical agent that inhibits platelet aggregation by selectively and irreversibly binding to the P2Y12 adenosine diphosphate (ADP) receptor on platelets. Known by Clopidogrel hemisulfate by manufacturers, clopidogrel commonly used to reduce the risk of heart disease and stroke in patients with a history of cardiovascular events. Clopidogrel bisulfate and Clopidogrel hydrogen sulfate are the same but in different synonym supplier traded names for the same chemical compound, which is a salt form of the antiplatelet drug clopidogrel. The name "bisulphate or bisulfae" is a less formal way of saying "hydrogen sulphate". CLB is Proton Pump Inhibitor (PPI). We are an established global Clopidogrel Bisulfate api supplier at 99%+ purity, ensuring minimal carry-over of impurities, and a broad range of various other critical pharmaceutical API supplier for semi-finished formulation and finished dosage manufacturers, providing comprehensive analytical (HPLC/NMR/MS) and supporting quality assurance documentation (COA/TDS/SDS) across all grades, detailed impurity mapping, and region-specific regulatory support. We ensure reliable lead times from R&D quantities through commercial-scale manufacturing, enabling partners to meet diverse global and regional requirements.